Direct inhibition of RAS: Quest for the Holy Grail?
Direct inhibition of RAS: Quest for the Holy Grail?
复制标题
DOI：
10.1016/j.semcancer.2017.12.005
复制
发表时间：
2019-03
影响因子：
14.5
通讯作者：
O'Bryan JP
中科院分区：
文献类型：
--
作者：
Spencer-Smith R;O'Bryan JP
RAS GTPases (H-, K-, and N-RAS) are the most frequently mutated oncoprotein family in human cancer. However, the relatively smooth surface architecture of RAS and its picomolar affinity for nucleotide have given rise to the assumption that RAS is an “undruggable” target. Recent advancements in drug screening, molecular modeling, and a greater understanding of RAS function have led to a resurgence in efforts to pharmacologically target this challenging foe. This review focuses on the state of the art of RAS inhibition, the approaches taken to achieve this goal, and the challenges of translating these discoveries into viable therapeutics.
登录
查看更多内容
DOI：
10.1073/pnas.96.12.7065
发表时间：
1999-06-08
影响因子：
11.1
作者：
Ahmadian, MR;Zor, T;Scheffzek, K
通讯作者：
Scheffzek, K
影响因子：
64.8
作者：
FERAMISCO, JR;CLARK, R;MCCORMICK, F
通讯作者：
MCCORMICK, F
影响因子：
5.3
作者：
Choi, Dong-Ki;Bae, Jeomil;Kim, Yong-Sung
通讯作者：
Kim, Yong-Sung
DOI：
10.1073/pnas.0903907107
发表时间：
2010-01-19
影响因子：
11.1
作者：
Abankwa, Daniel;Gorfe, Alemayehu A.;Hancock, John F.
通讯作者：
Hancock, John F.
影响因子：
11.2
作者：
Bai, YF;Edamatsu, H;Kataoka, T
通讯作者：
Kataoka, T